{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:07:39Z","timestamp":1789060059354,"version":"build-2803163510"},"reference-count":40,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LQ24H080009"],"award-info":[{"award-number":["LQ24H080009"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Young Taishan Scholar Foundation of Shandong Province","award":["tsqn202312325"],"award-info":[{"award-number":["tsqn202312325"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170123"],"award-info":[{"award-number":["82170123"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300144"],"award-info":[{"award-number":["82300144"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021MH132"],"award-info":[{"award-number":["ZR2021MH132"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hyperlipidemia is prevalent in primary immune thrombocytopenia (ITP) and may exacerbate bleeding severity and compromise treatment responses. Statins possess lipid-lowering and anti-inflammatory properties, but their influence on corticosteroid therapy in ITP patients with hyperlipidemia remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to compare the efficacy and safety of initial corticosteroid therapy between patients with or without concomitant statin use for pre-existing hyperlipidemia in a cohort of newly diagnosed ITP patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A multicenter retrospective propensity score-matched study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Newly diagnosed ITP patients with pre-existing hyperlipidemia from 9 medical centers were analyzed. Patients were divided into 2 groups based on statin use (statin\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . non-statin). Propensity score matching (PSM) was employed to balance baseline characteristics. Treatment outcomes, including response rates, duration of response (DOR), and safety, were compared.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After PSM, 104 patients (52 per group) were included. Baseline characteristics were comparable. Initial response rates were similar between the statin and non-statin groups (67.3%\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      65.4%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.836), with the 95% confidence interval (CI) for the between-group risk difference ranging from -15.83% to 19.51%. The median time to response was numerically shorter in the statin group, although this difference did not reach statistical significance (4 [2-8] days\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      5 [2-12] days,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.054). Notably, the sustained response (SR) rate at 6 months was significantly higher in the statin group compared to the non-statin group (50.0%\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      30.8%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.046), with the 95% CI for the between-group risk difference ranging from 0.41% to 36.25%. Kaplan-Meier analysis also demonstrated a significant longer duration of response (DOR) in the statin group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.044). No serious adverse events were observed in either group during follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this retrospective, propensity score-matched cohort, concomitant statin use was associated with higher 6-month SR rates and longer DOR in newly diagnosed ITP patients with pre-existing hyperlipidemia, without an apparent increase in serious adverse events. These observational findings warrant further validation in larger, prospective cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207261484030","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:03:35Z","timestamp":1788797015000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Corticosteroids plus statins in patients with primary immune thrombocytopenia and hyperlipidemia: A multicenter retrospective cohort study"],"prefix":"10.1177","volume":"17","author":[{"given":"Xiran","family":"Hou","sequence":"first","affiliation":[{"name":"Qilu Hospital of Shandong University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Qilu Hospital of Shandong University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Chen","sequence":"additional","affiliation":[{"name":"Jining No. 1 People\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Sun","sequence":"additional","affiliation":[{"name":"Central Hospital Affiliated to Shandong First Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaofeng","family":"Dong","sequence":"additional","affiliation":[{"name":"Heze Municipal Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Qilu Hospital of Shandong University Dezhou Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Lv","sequence":"additional","affiliation":[{"name":"Jinan City People\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Liu","sequence":"additional","affiliation":[{"name":"Tai\u2019an Central Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Gao","sequence":"additional","affiliation":[{"name":"Binzhou Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Hou","sequence":"additional","affiliation":[{"name":"Qilu Hospital of Shandong University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Peng","sequence":"additional","affiliation":[{"name":"Qilu Hospital of Shandong University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3200-2380","authenticated-orcid":false,"given":"Zhenyu","family":"Yan","sequence":"additional","affiliation":[{"name":"North China University of Science and Technology Affiliated Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1808-4498","authenticated-orcid":false,"given":"Xinguang","family":"Liu","sequence":"additional","affiliation":[{"name":"Qilu Hospital of Shandong University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01401-z"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000574"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000612"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S300717"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05466-1"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04829-4"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2016.09.001"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.953716"},{"issue":"4","key":"e_1_3_8_10_2","first-page":"361","article-title":"Safety and efficacy of splenectomy in immune thrombocytopenia","volume":"11","author":"Mishra K","year":"2021","unstructured":"Mishra K, Kumar S, Sandal R, et al. Safety and efficacy of splenectomy in immune thrombocytopenia. Am J Blood Res 2021; 11(4): 361\u2013372.","journal-title":"Am J Blood Res"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-020-00123-w"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06539-2"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000018400.39687.8C"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-023-00545-9"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/82219"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2015.11.002"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-824888"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6661847"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-807248"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"issue":"2","key":"e_1_3_8_21_2","first-page":"89","article-title":"Consensus of Chinese experts on diagnosis and treatment of adult primary immune thrombocytopenia (version 2016)]","volume":"37","year":"2016","unstructured":"Consensus of Chinese experts on diagnosis and treatment of adult primary immune thrombocytopenia (version 2016)]. Zhonghua Xue Ye Xue Za Zhi 2016; 37(2): 89\u201393. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2016.02.001","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1190934"},{"issue":"6","key":"e_1_3_8_23_2","first-page":"631","article-title":"Statin Therapy: Review of Safety and Potential Side Effects","volume":"32","author":"Ramkumar S","year":"2016","unstructured":"Ramkumar S, Raghunath A, Raghunath S. Statin Therapy: Review of Safety and Potential Side Effects. Acta Cardiol Sin 2016; 32(6): 631\u2013639. https:\/\/doi.org\/10.6515\/acs20160611a","journal-title":"Acta Cardiol Sin"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-061476"},{"issue":"8","key":"e_1_3_8_25_2","first-page":"617","article-title":"Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia (version 2020)]","volume":"41","author":"Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association","year":"2020","unstructured":"Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia (version 2020)]. Zhonghua Xue Ye Xue Za Zhi 2020; 41(8): 617\u2013623. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2020.08.001","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111827"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2025.156971"},{"key":"e_1_3_8_28_2","doi-asserted-by":"publisher","DOI":"10.1155\/mi\/5578929"},{"key":"e_1_3_8_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2005.12.006"},{"key":"e_1_3_8_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-022-01017-3"},{"issue":"11","key":"e_1_3_8_31_2","first-page":"747","article-title":"Cellular and Molecular Links between Autoimmunity and Lipid Metabolism","volume":"42","author":"Ryu H","year":"2019","unstructured":"Ryu H, Kim J, Kim D, et al. Cellular and Molecular Links between Autoimmunity and Lipid Metabolism. Mol Cells 2019; 42(11): 747\u2013754. https:\/\/doi.org\/10.14348\/molcells.2019.0196","journal-title":"Mol Cells"},{"key":"e_1_3_8_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1839"},{"key":"e_1_3_8_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107614"},{"key":"e_1_3_8_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2012.02.023"},{"key":"e_1_3_8_35_2","doi-asserted-by":"publisher","DOI":"10.15586\/aei.v52i5.1100"},{"key":"e_1_3_8_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108282"},{"key":"e_1_3_8_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17938"},{"key":"e_1_3_8_38_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI148552"},{"key":"e_1_3_8_39_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.10.7416"},{"key":"e_1_3_8_40_2","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M010876"},{"key":"e_1_3_8_41_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2011.540568"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261484030","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207261484030","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261484030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:16:42Z","timestamp":1789057002000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207261484030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"alternative-id":["10.1177\/20406207261484030"],"URL":"https:\/\/doi.org\/10.1177\/20406207261484030","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"article-number":"20406207261484030"}}